Choose excellence, choose WuXi Biology – your reliable partner in Targeted Protein Degradation (TPD) drug discovery. Since 2016, we have developed comprehensive discovery platforms capable of investigating the complete TPD functional cycle, from binary and ternary complex formation to protein ubiquitination and degradation. Our broad and deep expertise spans diverse TPD modalities, including PROTACs®, molecular …Read More >

Antibody-drug conjugates (ADCs) are increasingly demonstrating their value in cancer treatment, especially in combination therapies and for targeting resistant cancer cell populations.  The ability of ADCs to deliver highly potent cytotoxic payloads directly to cancer cells that express a target antigen makes them a promising approach for targeted therapy.  However, the complex structure and mechanism …Read More >

Since 2016, WuXi AppTec has built a comprehensive discovery platform focused on Targeted Protein Degraders (TPDs).  Our platform enables research teams to investigate the complete TPD functional cycle, from binary and ternary complex formation to protein ubiquitination and degradation.  Our end-to-end services encompass over 20 assay technologies, 10+ types of TPD molecules, and one-stop screening …Read More >

At this year’s annual meeting of the American Association for Cancer Research (AACR), WuXi Biology has been selected to present multiple posters detailing latest scientific insights, covering a range of cutting-edge topics from preclinical tumor model development and biomarker discovery, to the evaluation of novel anti-cancer therapies. Explore this quick overview of WuXi Biology’s pioneering …Read More >

Rheumatoid arthritis (RA) is a prevalent, chronic, autoimmune disease. The onset and progression of RA are closely associated with an aberrant immune response, in which immune cells accumulate excessively in target joints.  Most current, anti-rheumatic drugs only alleviate disease progression or ameliorate inflammation. Development of new RA therapies with increased efficacy represents an unmet medical …Read More >

Despite the excellent clinical response to paclitaxel therapy, drug resistance inevitably develops in subsequent treatments. The mechanisms for resistance to paclitaxel include drug efflux transporter overexpression, altered apoptotic gene expression, and changes associated with microtubules to reduce the influence of this chemotherapeutic agent. WuXi Biology has established gastric cancer and breast cancer cell lines that …Read More >

Radiopharmaceuticals have proven to be effective agents since they can be successfully applied for both diagnostics and therapy. Radionuclide drug conjugates (RDCs) combine a radioactive compound, a tailored-targeting molecule for specific receptors enriched on diseased cells, and a linker for stable attachment, enabling more effective radiation delivery and significantly reducing side effects by attacking only …Read More >

An inevitable challenge emerges over time as tumors develop drug resistance, resulting in treatment failure. This resistance is inherent to the tumor cells themselves, as well as tied to factors within the tumor microenvironment (TME). To bolster the research of innovative cancer drugs and to emulate real-world clinical scenarios of tumor resistance, WuXi Biology has …Read More >

Join WuXi AppTec at IMMUNOLOGY2024™. For this year’s annual meeting of the American Association of Immunologists (AAI), WuXi Biology has been selected to present five noteworthy posters, showcasing our panel of preclinical models representing urticaria, nephritis, rheumatoid arthritis, gout, and atopic dermatitis. Stop by Booth 777 to get your questions answered by one of our …Read More >